priceTarget News & Analysis
25 articles
Market Mood
NVIDIA (NVDA) Price Target Raised to $320 on $1.7 Trillion AI Forecast
Bank of America raised NVIDIA's (NVDA) price target from $300 to $320, citing a $1.7 trillion total addressable market forecast for AI data centers by 2030. The firm expects accelerating AI sales through 2026 and 2027, driven by new compute and memory architectures. NVIDIA's recent fiscal 2026 results showed revenue of $215.94 billion, up 66%, and net income of $120.07 billion. The stock currently trades at $226 with a P/E ratio of 45x and a consensus target of $269.17.
Read More
Adient (ADNT) Price Target Raised to $31 by Deutsche Bank and Stifel
Deutsche Bank raised its price target for Adient plc (ADNT) to $31 from $30 while maintaining a Buy rating. Stifel also increased its price target on ADNT to $28 from $26. On May 6, 2026, Adient reported Q2 adjusted EPS of $0.52, exceeding the consensus estimate of $0.44, with revenue of $3.87 billion compared to a $3.63 billion estimate. Additionally, Adient raised its FY26 revenue outlook to $14.8 billion, adjusted EBITDA outlook to $885 million, and free cash flow to $130 million, underscoring strong operational execution.
Read More
Acadia Healthcare (ACHC) Price Target Raised to $31 After Q1 Beat
Acadia Healthcare Company, Inc. (ACHC) received an upgraded price target from RBC Capital, increasing from $28 to $31 following its fiscal Q1 earnings beat. The firm maintained an Outperform rating on the stock. Similarly, Raymond James upgraded ACHC to Strong Buy, raising its price target from $25 to $39. The analysts noted an increased EBITDA and earnings outlook for 2026 and highlighted the company's strategy to achieve a $200 million target from underperforming facilities. This positive sentiment could potentially lead to an upward movement in ACHC's stock price in the near term.
Read More
Tesla (TSLA) Targets $2,600 Price by 2029 Amid AI Expansion
Cathie Wood has set a price target of $2,600 for Tesla Inc (TSLA) by 2029, primarily driven by advancements in AI and robotics. The company intends to increase its capital spending from $20 billion to $25 billion to support this strategic pivot. Additionally, Tesla aims to mass-produce its Optimus humanoid robot at a target of 1 million units annually by the late 2020s and potentially 10 million by the early 2030s. The global robotics market is anticipated to reach $416 billion by 2035, growing at an annual rate of around 14%, providing significant future growth potential for Tesla.
Read More
DTE Energy (DTE) Analysts Maintain Buy Rating with Price Target of $168
On May 5, analysts at Jefferies maintained a Buy rating on DTE Energy Company (DTE) but reduced the price target from $170 to $168. The firm expects DTE to experience a compound annual growth rate of 8% or more due to data center deals and a proposal aimed at reducing stock risk. DTE is also negotiating for 2 gigawatts of pipeline capacity, enhancing its growth opportunities. Analysts noted that DTE is currently trading at a 4% discount to the average peer price-to-earnings ratio, signaling potential value for investors.
Read More
ServiceNow (NOW) Price Target Set at $85 by KeyBanc
KeyBanc has reiterated an Underweight rating on ServiceNow (NOW) and set a price target of $85 following its Financial Analyst Day, during which CEO Bill McDermott announced a goal of $30 billion in subscription revenue by 2030. This target represents a 17.5% compound annual growth rate from 2027 to 2030. Additionally, ServiceNow aims to maintain a rule of 60 or higher by 2030. Currently, 90% of analysts rate ServiceNow as a Buy, with an average price target of $140, indicating a potential 52.16% upside from the current price of $92.01.
Read More
Goldman Sachs raises AMG price target to $405 on earnings strength
Goldman Sachs increased its price target for Affiliated Managers Group (AMG) to $405 based on strong earnings performance. This adjustment indicates a positive outlook for AMG, which may influence investor sentiment and trading activity. The revised target reflects a significant change, suggesting analysts expect continued robust financial results in the future. Such price target revisions can impact market prices and investor strategies around AMG shares.
Read More
Goldman Sachs Raises WisdomTree (WETF) Price Target to $16.80
Goldman Sachs has raised the price target for WisdomTree (WETF) to $16.80 following an acquisition announcement. This adjustment represents a positive outlook for the company’s future performance. The increase indicates confidence in the potential synergies and earnings generated from the acquisition. Price target revisions by major financial institutions can impact investor sentiment and market performance significantly.
Read More
Morgan Stanley Raises AAPL Price Target to $330, Maintains Overweight
On April 30, Morgan Stanley raised its price target for Apple Inc. (AAPL) from $315 to $330, maintaining an Overweight rating. The upgrade follows Apple’s March quarter results, where the Services division grew by 16.3% year-over-year, exceeding previous guidance of around 14%. For the upcoming June quarter, Apple forecasted a gross margin between 47.5% and 48.5%. Additionally, Morgan Stanley increased its fiscal 2026 EPS estimate from $8.63 to $8.89 and set the 2027 estimate at $10.23 while keeping a valuation multiple of 32 times earnings.
Read More
Relay Therapeutics (RLAY) Price Target Raised to Reflect Trial Data
Raymond James has increased its price target for Relay Therapeutics (RLAY) based on recent clinical trial data. The new target reflects improved expectations for the company's drug candidates following updates from the trials. This adjustment may influence investor sentiment and trading volumes in RLAY shares, as the anticipated results could lead to increased market interest. Analyst revisions of price targets are important indicators of future performance and investor confidence.
Read More
Chipotle (CMG) Price Target Reduced to $45 by RBC Capital
RBC Capital has decreased the price target for Chipotle Mexican Grill, Inc. (CMG) from $50 to $45 while maintaining a Buy rating ahead of its FQ1 2026 earnings report set for April 29. The average 12-month price target indicates potential upside of over 22% based on current levels. Analysts remain optimistic, with 67% of 42 analysts offering Buy ratings. RBC anticipates that same-store sales will slightly exceed consensus estimates, albeit cautioning that flat same-store sales guidance for fiscal 2026 may prevail due to consumer spending pressures.
Read More
Bank of America Cuts Pentair (PNR) Price Target to $88
Bank of America has reduced its price target for Pentair (PNR) to $88, indicating anticipated weakness for Q1. This reassessment may reflect broader concerns about Pentair's market performance and operational challenges. Investors should note this revised outlook as it could influence trading volumes and price movements for PNR shares. Adjustments from major financial institutions like Bank of America can significantly affect market sentiment and investor behavior.
Read More
D.R. Horton (DHI) Stock Price Target Raised Following Margin Beat
Evercore ISI has increased its price target for D.R. Horton (DHI) stock following a reported margin beat. The new target reflects positive performance metrics that could influence investor confidence and market perceptions. This adjustment may lead to increased trading volumes as investors react to the optimistic outlook. As market dynamics evolve, the revision in DHI’s price target could signal a shift in the company's growth potential and profitability.
Read More
Constellation Energy (CEG) Price Target Raised to $360 by Barclays
On April 4, Barclays reiterated its Overweight rating for Constellation Energy Corporation (CEG) and increased the price target to $360 from $356. The company anticipates 2026 earnings between $11 and $12 per share, with Barclays forecasting a rise to $19 per share by 2029. Constellation plans to invest $3.9 billion in capital expenditures in 2026 and has increased its share buyback authorization to $5 billion. This positions CEG to meet the increasing demand for clean electricity in the U.S., particularly following the record power demand seen in 2025.
Read More
Crescent Energy (CRGY) Price Target Raised to $19 After Oil Revision
KeyBanc has increased the price target for Crescent Energy (CRGY) from $15 to $19, representing a potential upside of over 50% from current levels. This revision follows an update in the oil price deck and expects current imbalances in crude and refined products to persist into summer 2026. Crescent Energy recently completed a $3.1 billion acquisition of Vital Energy, enhancing its growth potential amid commodity price volatility. The analyst maintains an 'Overweight' rating on CRGY shares, highlighting opportunities for investors in the current market climate.
Read More
TruBridge (TRUB) Stock Rated Overweight at $25 by Cantor Fitzgerald
Cantor Fitzgerald has reiterated its Overweight rating for TruBridge (TRUB) stock, setting a price target of $25. This rating suggests strong confidence in the stock's potential to perform well in the market. The recommendation could lead to increased trading activity and interest among investors. Evaluating the performance against peers may be essential for TruBridge's growth trajectory.
Read More
Alumis Stock Price Target Adjusted to $25 Amid Competitive Pressures
H.C. Wainwright has lowered its price target for Alumis's stock to $25, citing competitive pressures in the market. This adjustment reflects concerns regarding market dynamics that could impact the company's performance. As a result, this change may influence investor sentiment and trading strategies for Alumis shares going forward.
Read More
Leerink Increases Rocket Pharmaceuticals Price Target Following FDA Approval
Leerink has raised its price target for Rocket Pharmaceuticals following the FDA approval of its new treatment. The updated price target reflects a higher valuation of the stock amidst positive regulatory news. The company's performance may see improved trading volume and investor interest as a result of this approval. FDA approvals generally indicate potential revenue growth, impacting market sentiment in the biotech sector.
Read More
Stifel Sets $244 Price Target for IDEX Stock; Reiterates Buy Rating
Stifel has maintained a Buy rating on IDEX stock, assigning a price target of $244. This reiteration may influence investor perceptions and trading strategies. The price target indicates an expectation of significant appreciation in the stock price. Market participants often look at analyst ratings and targets to gauge potential future performance.
Read More
Cantor Fitzgerald Increases Centuri Holdings Price Target on Earnings Raise
Cantor Fitzgerald has raised its price target for Centuri Holdings, reflecting higher earnings expectations. The new price target indicates a positive outlook for the stock based on improved financial performance. This adjustment may positively influence investor sentiment towards Centuri Holdings, impacting its market performance. Key financial metrics that led to this change were not specified in the article.
Read More
Netflix (NFLX) Rated Outperform with $115 Target, Margin Growth Projections
On March 12, Bernstein SocGen Group reaffirmed an Outperform rating for Netflix, Inc. (NASDAQ: NFLX) with a price target of $115. The company reported a margin growth of 600 basis points in 2024 and 400 basis points in 2025, excluding Brazil's impact. For 2026, Netflix projects a 31.5% margin, up 50 basis points from 2025. Argus, however, lowered its price target from $141 to $110 while maintaining a Buy rating. This analysis reflects ongoing changes in Netflix's strategy and market position.
Read More
Apple Inc. Maintains Sector Weight Rating Amid 9% Spending Decline
On March 12, 2026, KeyBanc reaffirmed a Sector Weight rating for Apple Inc. (NASDAQ: AAPL), noting a 9% month-over-month decrease in indexed spending, compared to a three-year average drop of 4%. The firm indicated that this data aligns with forecasts, and its projections for fiscal year 2026 are consistent with expectations and slightly below consensus for fiscal year 2027. Additionally, on March 5, Rosenblatt raised its price target for Apple to $268, reflecting optimism on recent product releases including lower-end devices. This information may influence investor sentiment regarding AAPL's market performance.
Read More
Goldman Sachs Reiterates $250 Price Target for Nvidia Stock After GTC
Goldman Sachs has reiterated its $250 price target for Nvidia (NVDA) following the GTC event. At the time of writing on March 21, 2026, Nvidia was trading at $172.70. The firm emphasizes confidence in Nvidia's AI growth potential and maintains a buy rating. Key financial forecasts include revenues of $215 billion for 2026, $393.6 billion for 2027, $521.5 billion for 2028, and $634.8 billion for 2029. Nvidia's projected earnings per share (EPS) are 4.52 for 2026, rising to 15.41 by 2029.
Read More
UBS Upgrades Price Target for EchoStar (SATS) Amid Positive Market Outlook
UBS has raised its price target on EchoStar Corporation (SATS), signaling a positive outlook for the company's stock. This upgrade comes as EchoStar continues to strengthen its position in the satellite communications sector, aiming to capitalize on the growing demand for broadband services. Analysts believe this could influence investor sentiment, potentially leading to an increase in share prices as the market reacts to improved expectations. Keeping an eye on the performance of SATS may be crucial for investors amidst ongoing developments in the telecommunications industry.
Read More
UBS Increases Price Target on Iovance Biotherapeutics Amid Growth Potential
UBS has raised its price target on Iovance Biotherapeutics (NASDAQ: IOVA), signaling confidence in the company's future growth amid ongoing developments in its cell therapy treatments. The adjustment reflects a positive outlook on Iovance's clinical trials and market position in the biotech sector. The new price target could influence investor sentiment and trading activity in biotech stocks as analysts adjust their forecasts. Iovance's innovation in cancer therapeutics continues to attract significant attention from investors and stakeholders.
Read More